SCHEDULE: RA Capital Boosts SAB Biotherapeutics Stake to 9.9%

RA Capital Management and its affiliates increased their beneficial ownership in SAB Biotherapeutics, Inc. to 9.9% through the acquisition of pre-funded warrants.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") collectively beneficially own 7,311,225 shares of SAB Biotherapeutics, Inc. common stock, representing 9.9% of the class.
• This ownership includes 4,401,500 direct common shares, Series B preferred stock convertible into up to 12,738,500 common shares, preferred stock purchase warrants, and pre-funded warrants exercisable for up to 2,753,246 common shares.
• On March 19, 2026, RA Capital Healthcare Fund, L.P. purchased Pre-Funded Warrants for 2,753,246 shares of common stock at a price of $3.8499 per warrant share, totaling $10,599,721.78, which was funded by the working capital of the Fund.
• The acquisition of Pre-Funded Warrants was part of SAB Biotherapeutics' public offering in March 2026.
• Beneficial ownership blockers in the Preferred Stock and Pre-Funded Warrants currently prevent the Fund from converting or exercising if it would result in ownership exceeding 9.99% of the common stock outstanding, though this limit can be increased to 19.99% with 61 days' notice.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting continued institutional confidence and a strategic long-term investment by a reputable healthcare fund in SAB Biotherapeutics.

Positives

• Increased investment by a prominent healthcare-focused investment firm, RA Capital, signals continued confidence in SAB Biotherapeutics' prospects.
• The acquisition of pre-funded warrants provides RA Capital with significant potential upside exposure to SAB Biotherapeutics' common stock at a nominal exercise price of $0.0001 per share.
• The investment was part of a public offering, indicating SAB Biotherapeutics successfully raised capital to support its operations and development.

Negatives

• The beneficial ownership blocker limits RA Capital's immediate ability to convert all its convertible securities, potentially capping its direct ownership percentage and influence in the short term.

Risks

• Beneficial ownership blockers in the Preferred Stock and Pre-Funded Warrants prevent the Fund from converting or exercising if it would result in ownership exceeding 9.99% of the common stock outstanding, limiting immediate full realization of potential ownership.
• The ability to increase the beneficial ownership limit to 19.99% requires a 61-day notice period, which delays any potential increase in direct influence or ownership.

Future Outlook

The filing indicates RA Capital's continued strategic investment in SAB Biotherapeutics, with provisions allowing for a potential increase in beneficial ownership up to 19.99% after a 61-day notice period, suggesting a long-term interest in the company's trajectory.

Industry Context

StockSavvy.ai notes that increased institutional investment, particularly from specialized healthcare funds like RA Capital, often signals a positive long-term outlook for a biotechnology company. Such investments can provide crucial capital for R&D and clinical trials, which are capital-intensive in the biotech sector. This move suggests RA Capital sees value in SAB Biotherapeutics' pipeline or technology, aligning with a broader trend of strategic investments in promising biotech firms.

Comparison to Industry Standards

• RA Capital's 9.9% stake is a significant position for an institutional investor, often indicating a belief in substantial future growth, comparable to early-stage investments seen in companies like Moderna (MRNA) or BioNTech (BNTX) by specialized funds during their development phases.
• The use of pre-funded warrants with a nominal exercise price ($0.0001) is a common financing mechanism in biotech, allowing investors to secure future equity at a low cost while managing immediate dilution and beneficial ownership thresholds, similar to structures used by funds investing in companies like CRISPR Therapeutics (CRSP) or Editas Medicine (EDIT).
• The beneficial ownership blocker at 9.99% is a standard regulatory compliance measure to avoid triggering certain reporting requirements or control provisions, a practice observed across many public companies to manage shareholder activism thresholds.

Stakeholder Impact

• Shareholders: Existing shareholders may view the increased institutional investment as a positive signal, potentially leading to increased investor confidence and share price stability. The public offering itself would have caused some dilution.
• Company (SAB Biotherapeutics): The capital raised through the public offering, including RA Capital's investment, provides additional funding for operations, research, and development.

Next Steps

• RA Capital Healthcare Fund, L.P. may increase its maximum beneficial ownership percentage to any other percentage not exceeding 19.99% by providing 61 days' written notice to the Issuer.

Key Dates

Recommendation

The filing indicates a significant institutional investor, RA Capital, has increased its stake in SAB Biotherapeutics through a public offering. While this signals confidence and provides capital to the company, the filing itself is an ownership disclosure rather than a performance update. The beneficial ownership blocker at 9.99% also limits immediate upside from full conversion. Investors should hold and monitor future company performance and RA Capital's actions, especially regarding the potential increase in their ownership limit.

Keywords

SAB Biotherapeutics, RA Capital Management, Schedule 13D/A, Beneficial Ownership, Pre-Funded Warrants, Common Stock, Biotechnology Investment, Public Offering, Institutional Investor